BridgeBio to Present New Acoramidis Data on Heart Failure Events at AHA Meeting
Bitget2026/11/03 12:32- BridgeBio will present new acoramidis data in ATTR-CM at the American Heart Association Scientific Sessions in Chicago, November 6-9, 2026.
- ATTRibute-CM analyses scheduled for November 8 examine heart failure events, hospitalization risk and recovery following cardiovascular hospitalization.
- The company says the data strengthen acoramidis’ clinical profile in transthyretin amyloid cardiomyopathy.
- Acoramidis is marketed as Attruby in the U.S. and BEYONTTRA in several international markets.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
British Pound hits session highs at 1.3420 amid broadbased US Dollar weakness
Cybertruck orders far exceed pre-production capacity, Tesla (TSLA.US) to refund deposits to a large number of customers
Elon Musk stated that Tesla will refund the Cybertruck deposits to a significant number of customers.
Barrick Gold (B.US) Q3 Results Mixed: Benefiting from Gold Price Dividend While Facing Cost Pressures
Barrick Mining (B.US) will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 9.
Crypto prices
More
